1 Russell 2000 stock that deserves your attention and 2 we choose to steer clear of

Exploring Opportunities in the Russell 2000

The Russell 2000 index is a treasure trove for investors seeking emerging growth stories, as it features smaller companies with significant upside potential. However, these firms often lack the stability and financial strength of their larger counterparts, so careful analysis is essential when choosing where to invest.

Because navigating the small-cap landscape can be challenging, StockStory was created to help investors distinguish promising companies from those likely to underperform. Below, we highlight one Russell 2000 stock that shows strong promise, along with two others that may be best avoided for now.

Two Stocks to Consider Selling

Shoe Carnival (SCVL)

Market Capitalization: $566.1 million

Shoe Carnival (NASDAQ:SCVL) is a family footwear retailer known for its lively, carnival-themed shopping experience, offering popular shoe brands for all ages.

Why Might SCVL Be a Risky Bet?

• Same-store sales have been sluggish for the past two years, indicating limited expansion opportunities in its primary markets.
• With annual revenues of $1.14 billion, the company lacks the scale advantages enjoyed by larger industry players.
• Profitability has deteriorated, as earnings per share have declined at a faster rate than revenue over the past three years.

Currently trading at $20.03 per share, Shoe Carnival has a forward price-to-earnings ratio of 13.3.

Ocular Therapeutix (OCUL)

Market Capitalization: $2.09 billion

Ocular Therapeutix (NASDAQ:OCUL) is at the forefront of developing sustained-release treatments for eye conditions, utilizing its proprietary ELUTYX hydrogel technology to gradually deliver medication and potentially eliminate the need for frequent eye injections.

Why Might OCUL Be Worth Avoiding?

• The company has faced tough market conditions, with sales shrinking by 5.7% per year over the past two years.
• Operational efficiency has suffered, as its adjusted operating margin has dropped by 340.5 percentage points over the last five years.
• Capital requirements have increased, with free cash flow margin declining by 264.1 percentage points in the same period.

Ocular Therapeutix is currently valued at $9.56 per share, reflecting a forward price-to-sales ratio of 38.1.

One Stock to Keep on Your Radar

Astrana Health (ASTH)

Market Capitalization: $1.05 billion

Previously operating as Apollo Medical Holdings, Astrana Health (NASDAQ:ASTH) rebranded in early 2024. The company runs a tech-driven healthcare platform that empowers doctors to deliver coordinated care and thrive under value-based payment models.

What Makes ASTH Stand Out?

• Revenue has soared by 47.7% annually over the past two years, signaling robust market share gains.
• The company’s revenue outlook for the next year is highly positive, suggesting continued growth momentum.
• Earnings per share have grown at an impressive 11.6% annual rate over the past five years, outpacing industry peers.

With shares priced at $20.91 and a forward EV-to-EBITDA ratio of 6.3, Astrana Health could be an attractive opportunity.

Discover Even More Compelling Stocks

Don’t let your investment strategy rely on outdated trends. The risks associated with crowded trades are increasing every day.

The next generation of high-growth companies can be found in our curated list of Top 6 Stocks for this week. These high-quality picks have delivered a remarkable 244% return over the past five years (as of June 30, 2025).

Our 2020 selections included now-household names like Nvidia, which soared 1,326% from June 2020 to June 2025, as well as lesser-known companies such as Kadant, which achieved a 351% five-year return. Start your search for the next market leader with StockStory today.